Search results
Results from the WOW.Com Content Network
Nodular regenerative hyperplasia (NRH) is a rare liver disease, characterised by the growth of nodules within the liver, resulting in liver hyperplasia.While in many cases it is asymptomatic and thus goes undetected – or is only discovered incidentally while investigating some other medical condition – in some people it results in non-cirrhotic portal hypertension (NCPH).
Focal nodular hyperplasia (FNH) is the second most common benign tumor of the liver. [2] FNH is found in 0.2%– 0.3% of adults worldwide. [2] FNH is more common in females (10:1 female to male ratio) except in Japan and China, in which there is a more equal prevalence of cases between females and males. [2]
Benign liver tumors generally develop on normal or fatty liver, are single or multiple (generally paucilocular), have distinct delineation, with increased echogenity (hemangiomas, benign focal nodular hyperplasia) or absent, with posterior acoustic enhancement effect (cysts), have distinct delineation (hydatid cyst), lack of vascularization or show a characteristic circulatory pattern ...
This disease was first described by Hugh Edmondson in a 14-year-old female with no underlying liver disease. [26] The name fibrolamellar hepatocellular carcinoma was coined by Craig et al. in 1980. [27] It was not recognized as a distinct form of cancer by the WHO until 2010. [28]
MUTYH-associated polyposis (also known as MYH-associated polyposis) is an autosomal recessive polyposis syndrome. [1] The disorder is caused by mutations in both alleles (genetic copies) of the DNA repair gene, MUTYH.
Desmoplastic small-round-cell tumor (DSRCT) is an aggressive and rare cancer that primarily occurs as masses in the abdomen. [4] Other areas affected may include the lymph nodes, the lining of the abdomen, diaphragm, spleen, liver, chest wall, skull, spinal cord, large intestine, small intestine, bladder, brain, lungs, testicles, ovaries, and the pelvis.
Nodular sclerosing Hodgkin lymphoma ("NSHL") or Nodular sclerosis is a form of Hodgkin's lymphoma [1] that is the most common subtype of HL in developed countries. It affects females slightly more than males and has a median age of onset at ~28 years.
Severe adverse events identified during the EMILIA trial included hepatotoxicity (liver damage), including rare cases of liver failure, hepatic encephalopathy, and nodular regenerative hyperplasia; heart damage (dysfunction of the left ventricle); interstitial lung disease, including acute interstitial pneumonitis; thrombocytopenia; and ...